MedTrace Logo

Fruquintinib Combined With TAS-102 in Refractory Metastatic Colorectal Cancer

NCT06221423 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2024-01-24

No results posted yet for this study

Summary

Fruquintinib, as a standard treatment for refractory metastatic colorectal cancer (mCRC), has attracted increasing research efforts to explore its innovative strategies in combination with immunotherapy and chemotherapy because of its multi-target mechanism which enhances the sensitivity of the immune system and chemotherapy, aiming to further improve the survival benefits for mCRC patients. Trifluridine/tipiracil (TAS-102) is also a standard treatment for mCRC. This study aims to investigate the safety and effectiveness of the combined use of these two drugs in mCRC.

Conditions

Interventions

DRUG

Fruquintinib Combined With TAS-102

Fruquintinib Combined With TAS-102

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Jianmin Xu · Department of Colorectal Surgery, Zhongshan Hospital, Fudan University

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2024-05-31
Completion
2024-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06221423 on ClinicalTrials.gov